Antisense Therapeutics Limited (“ANP” or “the Company”) is pleased to report the primary efficacy results from its phase 2 clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase 2 trial met its primary efficacy endpoint.

READ FULL ARTICLE Curated publisher From News Medical